NEW YORK – Natera's personalized ctDNA assay technology has shown new potential as a tool to assess the efficacy of breast cancer neoadjuvant chemotherapy and potentially guide decisions regarding further adjuvant treatment after surgery.
NEW YORK – Natera's personalized ctDNA assay technology has shown new potential as a tool to assess the efficacy of breast cancer neoadjuvant chemotherapy and potentially guide decisions regarding further adjuvant treatment after surgery.
Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.